BRPI1009431A2 - pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema - Google Patents

pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema

Info

Publication number
BRPI1009431A2
BRPI1009431A2 BRPI1009431A BRPI1009431A BRPI1009431A2 BR PI1009431 A2 BRPI1009431 A2 BR PI1009431A2 BR PI1009431 A BRPI1009431 A BR PI1009431A BR PI1009431 A BRPI1009431 A BR PI1009431A BR PI1009431 A2 BRPI1009431 A2 BR PI1009431A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical
treating
subject
need
drug delivery
Prior art date
Application number
BRPI1009431A
Other languages
English (en)
Inventor
Gunnar Berge
Jo Erik Johnsrud Klaveness
Preben Houlberg Olesen
Svein Olaf Hustvedt
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of BRPI1009431A2 publication Critical patent/BRPI1009431A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
BRPI1009431A 2009-03-09 2010-03-09 pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema BRPI1009431A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15861309P 2009-03-09 2009-03-09
US24263009P 2009-09-15 2009-09-15
US25429109P 2009-10-23 2009-10-23
US25429309P 2009-10-23 2009-10-23
PCT/IB2010/000824 WO2010103404A1 (en) 2009-03-09 2010-03-09 Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof

Publications (1)

Publication Number Publication Date
BRPI1009431A2 true BRPI1009431A2 (pt) 2016-03-01

Family

ID=42727856

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009431A BRPI1009431A2 (pt) 2009-03-09 2010-03-09 pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema

Country Status (17)

Country Link
US (6) US9532963B2 (pt)
EP (4) EP2405903B1 (pt)
JP (4) JP6176894B2 (pt)
KR (3) KR101966874B1 (pt)
CN (3) CN110538148A (pt)
AU (1) AU2010222648B2 (pt)
BR (1) BRPI1009431A2 (pt)
CA (2) CA2754860C (pt)
CO (1) CO6501136A2 (pt)
EA (1) EA022028B1 (pt)
ES (3) ES2881885T3 (pt)
IL (1) IL215043A (pt)
MX (1) MX2011009503A (pt)
NZ (1) NZ595204A (pt)
PH (1) PH12019500030A1 (pt)
SG (1) SG174314A1 (pt)
WO (3) WO2010103402A1 (pt)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1009431A2 (pt) * 2009-03-09 2016-03-01 Pronova Biopharma Norge As pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
CN104042617A (zh) 2009-04-29 2014-09-17 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
SG10201912687WA (en) 2009-04-29 2020-02-27 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
EP3698781A1 (en) 2009-06-15 2020-08-26 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy
RU2758369C2 (ru) 2009-09-23 2021-10-28 Амарин Фармасьютикалз Айрлэнд Лимитед Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
JP5951489B2 (ja) * 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組成物
KR102073938B1 (ko) * 2009-10-23 2020-02-05 바스프 에이에스 지방산 오일 혼합물의 코팅된 캡슐 및 정제
MX2012004977A (es) 2009-10-29 2012-11-06 Acasti Pharma Inc Composiciones fosfolipídicas terapéuticas concentradas.
CN102811781B (zh) 2009-12-30 2015-06-24 巴斯夫制药（卡兰尼什）公司 用于纯化多不饱和脂肪酸的模拟移动床色谱分离方法
WO2011090493A1 (en) 2010-01-19 2011-07-28 Martek Biosciences Corporation Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
US11236351B2 (en) 2010-05-17 2022-02-01 Dow Agrosciences Llc Production of DHA and other LC PUFAs in plants
KR20130139896A (ko) * 2010-09-08 2013-12-23 프로노바 바이오파마 너지 에이에스 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물
WO2012032417A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
UA111475C2 (uk) * 2010-11-05 2016-05-10 Пронова Байофарма Нордж Ас Способи лікування із застосуванням ліпідних сполук
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US9119826B2 (en) * 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
WO2012112511A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
WO2012112531A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
US8952000B2 (en) * 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
EP2675446A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
WO2012112517A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8697676B2 (en) * 2011-06-15 2014-04-15 Ronald E Rosedale Omega-3 fatty acid nutriceutical composition and optimization method
US10383839B2 (en) * 2011-06-30 2019-08-20 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
US20140323569A1 (en) * 2011-07-21 2014-10-30 Krishna Raman Microbial oils enriched in polyunsaturated fatty acids
EP2734197A4 (en) 2011-07-21 2014-12-17 Dsm Ip Assets Bv FATTY ACID COMPOSITIONS
TW201307553A (zh) * 2011-07-26 2013-02-16 Dow Agrosciences Llc 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013072767A1 (en) * 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
AU2013235266B2 (en) 2012-03-20 2017-10-19 Particle Dynamics International, Llc Gelling agent-based dosage form
US20150125529A1 (en) * 2012-03-30 2015-05-07 Sancilio & Company, Inc. Omega-3 Fatty Acid Ester Compositions
US20160228397A1 (en) * 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US20150132389A1 (en) * 2012-03-30 2015-05-14 Sancilio & Company, Inc. Omega-3 Fatty Acid Ester Compositions
DK3072510T3 (da) * 2012-03-30 2019-08-12 Micelle Biopharma Inc Omega-3-fedtsyreestersammensætninger
US9480651B2 (en) * 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US10898458B2 (en) * 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
HK1206248A1 (en) 2012-05-07 2016-01-08 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
ES2985397T3 (es) 2012-05-14 2024-11-05 Nissui Corp Acido graso altamente insaturado o etil éster de ácido graso altamente insaturado con contaminantes ambientales reducidos y método para la producción de los mismos
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140194512A1 (en) * 2012-06-17 2014-07-10 Matinas Biopharma, Inc. Compositions comprising docosapentaenoic acid and methods of use
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
CN103015230B (zh) * 2012-11-27 2015-04-01 广州嘉德乐生化科技有限公司 一种单硬脂酸甘油酯和聚氧乙烯醚脂肪酸皂的组合物
CN104937103A (zh) * 2012-12-06 2015-09-23 玛特纳斯生物制药有限公司 ω-3五烯酸组合物及使用方法
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
AR094941A1 (es) 2013-02-28 2015-09-09 Olaf Hustvedt Svein Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla
EP2968246A4 (en) * 2013-03-13 2016-08-03 Matinas Biopharma Inc OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
CN105530927A (zh) 2013-07-18 2016-04-27 持田制药株式会社 ω-3脂肪酸的自乳化组合物
EP3023098B1 (en) * 2013-07-18 2020-06-24 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of omega-3 fatty acid
WO2015011724A2 (en) * 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP2883860B1 (fr) 2013-12-11 2016-08-24 Novasep Process Procédé chromatographique de production d'acides gras polyinsaturés
CN115109804A (zh) 2013-12-20 2022-09-27 玛拉可再生能源公司 从微生物中回收油的方法
BR112016015718B1 (pt) 2014-01-07 2021-12-07 Novasep Process Solutions Processo de purificação de aminoácidos aromáticos
EP3099289B1 (en) * 2014-01-28 2020-03-25 Fresenius Kabi Deutschland GmbH Composition comprising epa and dha triglycerides for parenteral administration
EA038458B1 (ru) 2014-04-09 2021-08-31 Палс Фармасьютикалс Пвт. Лтд. Стабильная водная нанодисперсия водонерастворимых биоактивных соединений и способ ее получения
BR112016028561A8 (pt) 2014-06-06 2021-06-29 Marine Ingredients Llc composição e forma de dosagem compreendendo um óleo marinho que compreende ácidos graxos, e, uso das mesmas
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN107073084B (zh) * 2014-11-05 2022-03-25 雅培制药股份有限公司 用于生产具有改善的安全特性的具有脂肪酶活性的组合物和适用于药物用途的组合物的方法
CN105614638A (zh) * 2014-11-28 2016-06-01 深圳市前海安测信息技术有限公司 Dha纳米乳及其制备方法和其在健康保健饮品中的应用
US11007161B1 (en) * 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10561627B2 (en) * 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
WO2016117057A1 (ja) 2015-01-21 2016-07-28 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
JP6806339B2 (ja) * 2015-06-02 2021-01-06 日東薬品工業株式会社 新規なトリグリセリド及びその用途
RU2655803C2 (ru) * 2016-03-10 2018-05-29 АД Смарт, СИА Фармацевтическая композиция для профилактики и лечения атеросклероза
KR102263900B1 (ko) * 2016-03-16 2021-06-14 골든 오메가 노르웨이 에이에스 오메가-3 지방산 유도체를 포함하는 분말 및 정제 및 이의 제조 방법
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
CN106072611A (zh) * 2016-06-20 2016-11-09 威海百合生物技术股份有限公司 一种含不饱和脂肪酸的多相稀释组合物
GB201611920D0 (en) * 2016-07-08 2016-08-24 Astrazeneca Ab Pharmaceutical compositions
EP3496709A4 (en) * 2016-08-12 2020-04-08 Pharmako Biotechnologies PTY Limited OMEGA-3 COMPOSITIONS AND PROCEDURES
WO2018054265A1 (zh) * 2016-09-20 2018-03-29 张碧婷 亲水性脂类组合物的包装组合物，其制备及调配方法和应用
AU2017380721B2 (en) 2016-12-22 2021-04-01 MARA Renewables Corporation Methods for producing biomass rich in DHA, palmitic acid and protein using a eukaryotic microorganism
CN107048405A (zh) * 2017-03-03 2017-08-18 武汉锶博睿医药技术有限公司 脂肪酸组件微胶囊及其制备方法
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586643A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
EP3586641A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3750535B1 (en) 2018-09-24 2025-12-31 Amarin Pharmaceuticals Ireland Limited METHODS FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
HUE072655T2 (hu) 2018-11-30 2025-12-28 Evonik Operations Gmbh Foszfolipidek és zsírsav-sók diszperzióját tartalmazó készítmény
CA3137085A1 (en) 2019-04-18 2020-10-22 Akershus Universitetssykehus Hf Combination therapy comprising an ffar4 agonist and an alpha-7 nachr agonist or positive modulator
KR102096391B1 (ko) * 2019-10-11 2020-04-06 (주)아이엠디팜 액상결정 구조체를 형성하는 오메가-3-지방산 조성물
CN110584084A (zh) * 2019-10-17 2019-12-20 广州白云山汉方现代药业有限公司 一种乳化稳定剂及含该乳化稳定剂的营养乳液
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US12359230B2 (en) 2020-04-03 2025-07-15 MARA Renewables Corporation Microbial oils with high levels of omega-3 fatty acids
CN113827547A (zh) * 2020-06-23 2021-12-24 南京清普生物科技有限公司 一种缓释制剂组合物
CN111729125B (zh) * 2020-07-31 2022-10-04 陕西佰傲再生医学有限公司 骨止血材料
JP2021008518A (ja) * 2020-10-21 2021-01-28 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
CN116981443A (zh) 2020-12-31 2023-10-31 多伦多大学管理委员会 用于水溶性差的极性溶质的完全可稀释自微乳化递送系统(smedds)
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN116407543B (zh) * 2021-12-29 2025-12-12 中国科学院上海药物研究所 Epa-ee纳米脂质组合物、及其制剂、制备方法和应用
KR20230161551A (ko) * 2022-05-18 2023-11-28 부광약품 주식회사 제제학적으로 안정성이 향상된 연질 캡슐
KR102895710B1 (ko) * 2022-11-24 2025-12-05 주식회사 노바웰스 자가유화전달시스템을 이용한 지용성 생리활성성분의 흡수력 증대를 위한 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (pt) 1971-05-24 1978-05-01
GB2033745B (en) * 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
AU552068B2 (en) * 1981-09-21 1986-05-22 Asama Chemical Co. Ltd. Preservation of edible oils
DE3381777D1 (de) 1982-12-09 1990-09-06 Advanced Drug Tech Einfach absorbierbare fettsaeureemulsionen.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
CA2063791C (en) 1989-08-17 2000-12-19 Michael John Story Hard gelatine capsule containing fat-soluble nutrients.
US5532002A (en) * 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5501077A (en) * 1994-05-27 1996-03-26 Springwell Dispensers, Inc. Thermoelectric water chiller
JPH0889167A (ja) 1994-09-27 1996-04-09 Nippon Oil & Fats Co Ltd 多価不飽和脂肪酸含有醗酵乳の製造方法
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
DE19608137A1 (de) * 1996-03-02 1997-09-04 Meyer Lucas Gmbh & Co Lipid-Zubereitungen für diätetische Zwecke
AU1509799A (en) 1997-12-05 1999-06-28 Chong Kun Dang Corporation Pharmaceutical composition containing cyclosporin
KR100587551B1 (ko) * 1997-12-10 2006-06-08 싸이클로스포린 테라퓨틱스 리미티드 오메가-3 지방산 오일을 함유하는 약학 조성물
AU1809499A (en) 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations
WO1999056727A2 (en) 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20050037065A1 (en) 1999-05-27 2005-02-17 Drugtech Corporation Nutritional formulations
DK1157692T3 (da) 2000-05-22 2006-02-06 Pro Aparts Investimentos E Con Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
ITMI20022511A1 (it) 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
WO2004056370A1 (en) 2002-12-20 2004-07-08 Pronova Biocare As Use of a fatty acid composition for treatment of male infertility
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
NZ552390A (en) * 2004-08-06 2010-01-29 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
EP1786414A4 (en) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
US20090030077A1 (en) * 2004-08-06 2009-01-29 Transform Pharmaceuticals Inc. Novel Fenofibrate Formulations and Related Methods of Treatment
AU2005274574B2 (en) * 2004-08-18 2011-03-17 Ace Aps Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists
US20060051462A1 (en) 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
WO2006077495A1 (en) * 2005-01-24 2006-07-27 Pronova Biocare As Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases
BRPI0607569A2 (pt) 2005-03-08 2009-09-15 Reliant Pharmaceuticals Inc composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária
CN102526733B (zh) 2005-07-08 2014-09-03 持田制药株式会社 用于预防心血管事件发病的组合物
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
ES2511772T3 (es) 2005-12-20 2014-10-23 Cenestra, Llc Formulaciones de ácidos grasos omega-3
US20090017118A1 (en) 2006-02-10 2009-01-15 Sportscom Danmark Aps Coated tablets, their methods of preparation, and related uses
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
EP2068861A4 (en) * 2006-07-21 2010-01-06 Reliant Pharmaceuticals Inc COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND USE THEREOF IN THE TREATMENT OF PERIPHERAL ARTERIES DISEASE AND INTERMITTENT CLAUDICATION
EP2049098A2 (en) * 2006-07-21 2009-04-22 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids for use in treating resistant hypertension
US7676518B2 (en) 2006-08-16 2010-03-09 Sap Ag Clustering for structured data
JP2010506920A (ja) 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
EP2136844B1 (en) * 2007-03-20 2018-10-31 SCF Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
AR065791A1 (es) 2007-03-23 2009-07-01 Novartis Ag Uso de una sal de cobre enmascarada
US20080261896A1 (en) * 2007-04-11 2008-10-23 Sinphar Pharmaceutical Co., Ltd. Testosterone generating and metabolizing enhancer
CA2692394A1 (en) 2007-07-06 2009-01-15 Seth J. Baum Fatty acid compositions and methods of use
EP2239882A4 (en) 2008-01-04 2016-11-02 Univ Yamanashi PROCEDURE FOR CONFIDENTIAL COMMUNICATION
CN101969932A (zh) 2008-01-10 2011-02-09 武田药品工业株式会社 胶囊制剂
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
US20100130608A1 (en) 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
BRPI1009431A2 (pt) * 2009-03-09 2016-03-01 Pronova Biopharma Norge As pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema
JP5951489B2 (ja) 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組成物
KR102073938B1 (ko) 2009-10-23 2020-02-05 바스프 에이에스 지방산 오일 혼합물의 코팅된 캡슐 및 정제

Also Published As

Publication number Publication date
JP6723009B2 (ja) 2020-07-15
US20190183838A1 (en) 2019-06-20
US9532963B2 (en) 2017-01-03
JP2018090600A (ja) 2018-06-14
KR101966874B1 (ko) 2019-04-08
EP2405895A4 (en) 2012-10-10
EA022028B1 (ru) 2015-10-30
CN104146955A (zh) 2014-11-19
ES2894340T3 (es) 2022-02-14
EA201171113A1 (ru) 2012-07-30
CO6501136A2 (es) 2012-08-15
EP2405903A1 (en) 2012-01-18
CA3065860A1 (en) 2010-09-16
US11523999B2 (en) 2022-12-13
MX2011009503A (es) 2011-09-28
KR20180032670A (ko) 2018-03-30
US10596142B2 (en) 2020-03-24
EP2405895A1 (en) 2012-01-18
US20170112795A1 (en) 2017-04-27
IL215043A (en) 2016-11-30
JP2020079286A (ja) 2020-05-28
EP2405902A1 (en) 2012-01-18
WO2010103402A1 (en) 2010-09-16
US11612579B2 (en) 2023-03-28
EP2405903B1 (en) 2024-04-10
CN110538148A (zh) 2019-12-06
US20210085632A1 (en) 2021-03-25
US11395811B2 (en) 2022-07-26
EP2405902A4 (en) 2012-10-10
KR20190039342A (ko) 2019-04-10
CA2754860A1 (en) 2010-09-16
EP2405902B1 (en) 2021-07-21
AU2010222648B2 (en) 2016-07-07
WO2010103404A1 (en) 2010-09-16
ES2979118T3 (es) 2024-09-24
US20120225945A1 (en) 2012-09-06
SG174314A1 (en) 2011-10-28
EP3915554A1 (en) 2021-12-01
NZ595204A (en) 2014-11-28
IL215043A0 (en) 2011-11-30
EP2405903A4 (en) 2012-10-10
PH12019500030A1 (en) 2020-02-10
JP6176894B2 (ja) 2017-08-09
US10028928B2 (en) 2018-07-24
CN102421422A (zh) 2012-04-18
US20120196934A1 (en) 2012-08-02
ES2881885T3 (es) 2021-11-30
CA2754860C (en) 2020-02-25
WO2010119319A1 (en) 2010-10-21
EP2405895B1 (en) 2021-05-12
KR102118478B1 (ko) 2020-06-04
AU2010222648A1 (en) 2011-10-06
KR101841756B1 (ko) 2018-03-23
JP2012519728A (ja) 2012-08-30
JP7199389B2 (ja) 2023-01-05
JP2016128425A (ja) 2016-07-14
US20120232141A1 (en) 2012-09-13
KR20110126746A (ko) 2011-11-23

Similar Documents

Publication Publication Date Title
BRPI1009431A2 (pt) pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema
BRPI1014139A2 (pt) sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo.
BR112012013589A2 (pt) dispositivo e método para envio de dois ou mais agentes de fármaco
BRPI0818129A2 (pt) Sistema de transporte e administração de medicamento seguro
BR112013012198A2 (pt) cateter, sistema de formação de imagem médica e produto de programa de computador
BR112015005096A2 (pt) dispositivo, método, e sistema de suprimento de conteúdo, e, programa.
BR112013012818A2 (pt) módulo medicamentoso e sistema de administração de fármaco
BRPI1013399A2 (pt) sistema de entrega de fármaco intervencional e métodos associados
BR112012002981A2 (pt) sistema de liberação de fármaco oftálmico contendo fosfolipídio e colesterol.
BR112013021971A2 (pt) sistema médico e método.
EP3323405C0 (en) SYSTEM AND METHOD FOR DISPENSING MEDICATION
BR112012025956A2 (pt) sistema médico, aparelho e método
BRPI0814759A2 (pt) Sistema de administração e notificação de medicamento específico de paciente
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
IL229340A0 (en) Device, system and auxiliary method for administering injected drugs and their administration
BRPI1014170A2 (pt) métodos para prover conteúdo marcado a um paciente, e para prover conteúdo de assistência médica a pacientes, e, sistema de fornecimento de conteúdo de assistência médica marcado
BR112014010992A2 (pt) sistema sensor para detecção de uma substância em um dialisato, dispositivo de diálise e método para detecção de amônio em um dialisato
BR112012000786A2 (pt) conjunto de mancal de impulso, sistema de direção, e dispositivo de envio de medicamento
EP2911717A4 (en) DEVICE, SYSTEM AND METHOD FOR TRACKING THE DELIVERY OF A MEDICAMENT
IL210883A0 (en) Drug delivery system and method of munufacturing thereof
BRPI1015947A2 (pt) dispositivos para distribuição de fármacos e sistemas e métodos relacionados
BR112013029187A2 (pt) método e sistema para estabelecimento do formato da cavidade de acesso à oclusão no tratamento endodôntico
BRPI1016147A2 (pt) sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino
BR112013009801A2 (pt) sistema de processamento de imagens médicas, estação de trabalho, método de processamento de imagens médicas e produto de programa de computador
EP2482870A4 (en) SYSTEM AND METHOD FOR THE DISTINCTION OF CONTAINERS IN THE ADMINISTRATION OF MEDICINAL PRODUCTS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/232 (2006.01), A23L 33/10 (2016.01), A23L

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]